Recombinant erythropoietin - Prolong Pharmaceuticals/Zydus Cadila

Drug Profile

Recombinant erythropoietin - Prolong Pharmaceuticals/Zydus Cadila

Alternative Names: EPEG; PEG-EPO; PEGEPO - Cadila/Prolong; Pegylated erythropoietin - Cadila/Prolong; ZY-7318

Latest Information Update: 06 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prolong Pharmaceuticals; Zydus Cadila
  • Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaemia; Beta-thalassaemia

Most Recent Events

  • 25 Jan 2018 Recombinant erythropoietin is still in phase I trials for anaemia in India (Zydus pipeline, January 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anaemia in India (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top